Privacy Policy

Last updated: [Date]

1. Introduction

Welcome to the AI Educators and Enlightenment Learning Platform ("Platform"). We are committed to protecting your privacy and ensuring the security of your personal information. This Privacy Policy is designed to help you understand how we collect, use, disclose, and safeguard your personal data when you use our Platform.

2. Information We Collect

2.1. Account Information: When you create an account on our Platform, we collect information such as your name, email address, username, and password.

2.2. Profile Information: You may choose to provide additional information to build your profile, including a profile picture, professional background, and educational interests.

2.3. Payment Information: If you make purchases on our Platform, we may collect payment information such as credit card details or other financial information, which is processed securely through third-party payment processors.

2.4. User Content: We collect the content you submit or upload to the Platform, including but not limited to educational materials, course content, comments, and communications with other users.

2.5. Usage Information: We gather information about how you interact with the Platform, including your browsing history, search queries, and the pages you view.

3. How We Use Your Information

3.1. To Provide Services: We use your information to provide and improve the services offered on the Platform, including personalized learning experiences, course recommendations, and communication tools for educators and learners.

3.2. Communication: We may send you emails, notifications, and announcements related to your account, courses, and updates to our services.

3.1. To Provide Services: We use your information to provide and improve the services offered on the Platform, including personalized learning experiences, course recommendations, and communication tools for educators and learners.

3.1. To Provide Services: We use your information to provide and improve the services offered on the Platform, including personalized learning experiences, course recommendations, and communication tools for educators and learners.

4 Security

We take reasonable measures to protect your personal information, but no method of transmission over the internet or electronic storage is entirely secure. We strive to safeguard your information, but we cannot guarantee its absolute security.

5. Changes to this Privacy Policy

We may update this Privacy Policy from time to time. Any changes will be posted on this page, and the "Last updated" date at the beginning of the policy will be revised accordingly. Please review this policy periodically to stay informed of our practices.

6. Contact Us

If you have any questions or concerns about this Privacy Policy or your personal information, please contact us at [Contact Email Address]. By using our Platform, you agree to the terms of this Privacy Policy. If you do not agree with the terms herein, please do not use our services. Thank you for choosing AI Educators and Enlightenment Learning Platform.

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.

For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

© Phagenesis Inc. 2026. All rights reserved.

FDA has provided de novo classification for the Phagenyx® System and it is available for sale in the United States.



© Phagenesis Limited 2026. All rights reserved.

The Phagenyx® system is CE marked and is available for sale only in the European Economic Area, UK and Switzerland.

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.

For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

© Phagenesis Inc. 2026. All rights reserved.

FDA has provided de novo classification for the Phagenyx® System and it is available for sale in the United States.



© Phagenesis Limited 2026. All rights reserved.

The Phagenyx® system is CE marked and is available for sale only in the European Economic Area, UK and Switzerland.

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.

For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.

© Phagenesis Inc. 2026. All rights reserved.

FDA has provided de novo classification for the Phagenyx® System and it is available for sale in the United States.



© Phagenesis Limited 2026. All rights reserved.

The Phagenyx® system is CE marked and is available for sale only in the European Economic Area, UK and Switzerland.